MONDAY, Nov. 24, 2025 (HealthDay News) — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in ...

Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock ...

The success of obesity drug Mounjaro turned Eli Lilly into the first $1 trillion drugmaker on Friday, while Danish rival Novo ...

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

We asked top investors at firms like A16z and Kleiner Perkins to name the healthcare startups they've been watching this year ...

US stocks surged on Monday to start the shortened Thanksgiving trading week as US policymakers buoyed hopes for an ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, driven not only by outstanding earnings and a notable margin increase, but ...

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding ...